Travere Therapeutics is committed to research and development of new therapies for rare diseases.
Investigational therapy: Cholic acid
Therapeutic area: BASD; PBD-ZSD with liver involvement
Study type: Observational
Learn more: NCT03115086
On September 5, 2023, Travere Therapeutics announced that Mirum Pharmaceuticals acquired all of Travere’s rights and assets related to Cholbam®. For more information please visit mirumpharma.com.
Therapeutic area: HCU
Study type: Observational
Learn more: hcuconnection.com | NCT02998710
Therapeutic area: FSGS; IgAN
Study type: Phase 2
Learn more: eppikclinicalstudy.com | NCT05003986
Therapeutic area: IgAN
Study type: Phase 2
Learn more: NCT05856760
Investigational therapy: Chenodeoxycholic acid
Therapeutic area: CTX
Study type: Phase 3
Learn more: CTXrestore.com | NCT04270682
On September 5, 2023, Travere Therapeutics announced that Mirum Pharmaceuticals acquired all of Travere’s rights and assets related to Chenodal®. For more information please visit mirumpharma.com.
Investigational therapy: Pegtibatinase (TVT-058)
Therapeutic area: HCU
Study type: Phase 1/2
Learn more: hcuconnection.com | NCT03406611
Therapeutic area: FSGS; IgAN
Study type: Observational
Learn more: NCT05200871
Investigational therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 3
Learn more: NCT03493685
Investigational therapy: Sparsentan
Therapeutic area: IgAN
Study type: Phase 3
Learn more: NCT03762850
Investigational Therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 2
Learn more: NCT01613118